Abstract
This thesis places one of the most serious public health threats facing the world today — antimicrobial resistance (AMR) — at centre stage. It examines the intersection between the AMR crisis and pharmaceutical regulation and policy, exploring the extent to which selected regulatory and policy mechanisms can contribute to addressing this pressing challenge. Through a series of case studies, the thesis analyses key factors relevant to tackling AMR, including the appropriate use of antimicrobials, incentives to stimulate the development of new antimicrobial agents, and other regulatory and policy tools available to support a more effective response.
| Original language | English |
|---|---|
| Qualification | Doctor of Philosophy |
| Awarding Institution |
|
| Supervisors/Advisors |
|
| Award date | 8 Apr 2026 |
| Publisher | |
| Print ISBNs | 978-94-6537-319-5 |
| DOIs | |
| Publication status | Published - 8 Apr 2026 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- antimicrobial resistance
- old and new antibiotics
- appropriate and rational use of antibiotics
- the current and new EU Pharmaceutical Legislation
- European Medicines Agency
- incentives
- European regulatory measures (e.g. referral procedures) and tools (e.g. Scientific Advice)
- COVID-19
- medicine product information
Fingerprint
Dive into the research topics of 'The role of pharmaceutical regulation and policy in combatting antimicrobial resistance (AMR)'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver